Opinion|Videos|September 26, 2024
Recent Updates: REACH3, ROCKstar, and RWD
Medical experts discuss the recent updates presented at ASH 2023 and TANDEM 2024.
Advertisement
Video content above is prompted by the following:
- Briefly discuss recent updates presented at ASH 2023 and TANDEM 2024:
- 3-year analysis of REACH3, ASH 2023
- 3-year follow-up of the ROCKstar study, TANDEM 2024
- Brie fly discuss available real-world data (RWD) with ruxolitinib (Spałek A, et al. Pol Arch Intern Med. 2023) and ibrutinib (Chin KK, et al. Transplant Cell Ther. 2021;White J, et al. Transplant Cell Ther. 2023).
Advertisement
Related to this article
A pilot study represents a milestone toward testing a faster, more powerful, and potentially less-toxic form of radiation therapy for cancer treatment.
Oral azacitidine and cedazuridine met the end point of total cycle azacitidine exposure vs subcutaneous azacitidine in MDS or CMML.
UTRxMYCN M1-14 received orphan drug status for soft tissue sarcoma and RPDD for rhabdomyosarcoma.
Interim data showed that the BCMA-directed CAR T-cell therapy NXC-201 generated complete responses in relapsed/refractory AL amyloidosis.
Estelamari Rodriguez, MD, MPH, discusses the rationale, design, and practice implications of the phase 3 RELATIVITY-1093 trial in nonsquamous NSCLC.
Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
The third BLA submission for tabelecleucel follows 2 CRLs and includes updated ALLELE data with additional patients and longer follow-up.
A New England Journal of Medicine report describes complete hepatoblastoma regression in a 3-year-old treated with a novel immunotherapy.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Plinabulin Plus Docetaxel in Post-ICI Non-Squamous NSCLC
2
Breast Cancer Experts Highlight Abstracts to Watch at ESMO 2026
3
Navigating DLL3-Targeting T-Cell Engagers and the Evolving Small Cell Lung Cancer Treatment Landscape
4
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
5